Ellen Kurek

News
Immune Checkpoint Inhibitors May Have Been Used Inappropriately in Half of Study Patients with Advanced Cancer Who Were Near the End of Life
05/18/2022
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors...
05/18/2022
Journal of Clinical Pathways
News
Comparative Effectiveness of Ciltacabtagene Autoleucel vs Physician’s Choice of Therapy for Relapsed or Refractory Multiple Myeloma
05/16/2022
Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.
Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.
Ciltacabtagene autoleucel...
05/16/2022
Journal of Clinical Pathways
News
Progression-Free Survival Associated With Olaparib With or Without Cediranib vs Platinum-Based Chemotherapy in Women With High-Grade Ovarian Cancer
04/08/2022
Study findings suggest that neither olaparib monotherapy or olaparib plus cediranib increased progression-free survival when compared with platinum-based chemotherapy in women with high-grade serous or endometroid ovarian cancer sensitive to...
Study findings suggest that neither olaparib monotherapy or olaparib plus cediranib increased progression-free survival when compared with platinum-based chemotherapy in women with high-grade serous or endometroid ovarian cancer sensitive to...
Study findings suggest that...
04/08/2022
Journal of Clinical Pathways
News
Health Care Resource Utilization and Costs Associated With Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer
06/09/2022
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct...
06/09/2022
Journal of Clinical Pathways
News
Retrospective Study Shows Variations in BRAF Test Results in Turnaround Time Among Patients With Melanoma
04/28/2022
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma,...
04/28/2022
Journal of Clinical Pathways
Conference Coverage
Standardizing Utilization of Biosimilars in Oncology
07/06/2022
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent...
07/06/2022
Journal of Clinical Pathways
News
For Relapsed or Refractory Diffuse Large B-cell Lymphoma, Tisa-cel Resulted in Lower Inpatient Health Care Resource Utilization and Non-CAR-T Costs Than Axi-cel
05/18/2022
Researchers at Oregon Health and Science University compared the cost, health care resource utilization, and adverse events of chimeric antigen receptor T-cell therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma.
Researchers at Oregon Health and Science University compared the cost, health care resource utilization, and adverse events of chimeric antigen receptor T-cell therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma.
Researchers at Oregon Health and...
05/18/2022
Journal of Clinical Pathways
News
Progression-Free Survival Associated With Alectinib vs Crizotinib Among Patients With Advanced NSCLC
06/09/2022
Researchers in China studied 168 patients over three 3 to determine the benefits of tyrosine kinase inhibitor therapy in patient s with ALK-positive locally advanced or metastatic NSCLC.
Researchers in China studied 168 patients over three 3 to determine the benefits of tyrosine kinase inhibitor therapy in patient s with ALK-positive locally advanced or metastatic NSCLC.
Researchers in China studied 168...
06/09/2022
Journal of Clinical Pathways
News
Experts Provide Algorithm for Use of Bevacizumab and PARP Inhibitors in Patients With Newly Diagnosed, Advanced Ovarian Cancer
04/07/2022
Avelumab and atezolizumab may have limited impact on the clinical outcome of patients with newly diagnosed ovarian carcinoma, according to recent study findings.
Avelumab and atezolizumab may have limited impact on the clinical outcome of patients with newly diagnosed ovarian carcinoma, according to recent study findings.
Avelumab and atezolizumab may...
04/07/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use